An Exploratory Study to Evaluate the Safety and Preliminary Efficacy of KRAS-Specific Autologous TCR-T Cells in Advanced Solid Tumors
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs CRTKVA-11 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Corregene Biotechnology
- 17 Jan 2025 New trial record